Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer

BACKGROUND: 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fumet, Jean-David, Isambert, Nicolas, Hervieu, Alice, Zanetta, Sylvie, Guion, Jean-Florian, Hennequin, Audrey, Rederstorff, Emilie, Bertaut, Aurélie, Ghiringhelli, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012564/
https://www.ncbi.nlm.nih.gov/pubmed/29942666
http://dx.doi.org/10.1136/esmoopen-2018-000375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012564/
https://www.ncbi.nlm.nih.gov/pubmed/29942666
http://dx.doi.org/10.1136/esmoopen-2018-000375

Ejemplares similares